Sarepta Therapeutics (NASDAQ:SRPT) Receives Underperform Rating from Needham & Company LLC

Needham & Company LLC reiterated their underperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report published on Monday,Benzinga reports.

Other equities research analysts also recently issued reports about the company. Scotiabank upgraded Sarepta Therapeutics from a “sector perform” rating to a “sector outperform” rating and set a $80.00 price target for the company in a report on Friday, June 6th. Evercore ISI cut Sarepta Therapeutics from an “outperform” rating to an “inline” rating and set a $50.00 target price for the company. in a research note on Thursday, May 8th. UBS Group restated a “neutral” rating on shares of Sarepta Therapeutics in a report on Monday, July 21st. Bank of America reiterated an “underperform” rating on shares of Sarepta Therapeutics in a report on Wednesday, July 23rd. Finally, Piper Sandler dropped their price objective on shares of Sarepta Therapeutics from $32.00 to $18.00 and set a “neutral” rating on the stock in a report on Monday, July 21st. Seven research analysts have rated the stock with a sell rating, fifteen have given a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $51.42.

Sarepta Therapeutics Stock Up 16.2%

Shares of NASDAQ SRPT opened at $13.86 on Monday. Sarepta Therapeutics has a 52-week low of $10.41 and a 52-week high of $150.48. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.46 and a current ratio of 4.02. The stock has a market cap of $1.36 billion, a P/E ratio of -5.15 and a beta of 0.45. The firm has a 50 day moving average price of $25.64 and a 200 day moving average price of $62.85.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The firm had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. During the same period last year, the firm earned $0.73 EPS. Sarepta Therapeutics’s quarterly revenue was up 80.2% on a year-over-year basis. Analysts expect that Sarepta Therapeutics will post 2.67 EPS for the current year.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in SRPT. Capital International Investors grew its stake in shares of Sarepta Therapeutics by 38.9% in the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock valued at $1,057,482,000 after buying an additional 2,437,855 shares in the last quarter. Farallon Capital Management LLC lifted its stake in Sarepta Therapeutics by 11.1% in the fourth quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company’s stock valued at $348,368,000 after acquiring an additional 285,100 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Sarepta Therapeutics by 27.9% in the 1st quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company’s stock valued at $168,907,000 after acquiring an additional 577,848 shares during the period. T. Rowe Price Investment Management Inc. increased its stake in shares of Sarepta Therapeutics by 2.1% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 1,997,991 shares of the biotechnology company’s stock worth $127,512,000 after purchasing an additional 41,408 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Sarepta Therapeutics by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 1,706,353 shares of the biotechnology company’s stock valued at $207,538,000 after purchasing an additional 9,999 shares during the period. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.